Stockscreener 앱 받기
0.279
63.92%
0.1088
시간 외 거래:
.23
-0.049
-17.56%
전일 마감가:
$0.1702
열려 있는:
$0.27
하루 거래량:
304.66M
Relative Volume:
54.79
시가총액:
$16.61M
수익:
-
순이익/손실:
$-51.21M
주가수익비율:
-0.0357
EPS:
-7.82
순현금흐름:
$-44.62M
1주 성능:
+44.56%
1개월 성능:
+2.16%
6개월 성능:
-65.11%
1년 성능:
-88.03%
1일 변동 폭
$0.2106
$0.3895
1주일 범위
$0.17
$0.3895
52주 변동 폭
$0.13
$2.68
Aptose Biosciences Inc Stock (APTO) Company Profile
명칭
Aptose Biosciences Inc
전화
310-849-8060
주소
66 WELLINGTON STREET WEST, SUITE 5300, TORONTO, ON
APTO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APTO
Aptose Biosciences Inc
|
0.279 | 16.61M | 0 | -51.21M | -44.62M | -7.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aptose Biosciences Inc Stock (APTO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-10-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-09-22 | 개시 | Alliance Global Partners | Buy |
| 2020-02-20 | 개시 | Maxim Group | Buy |
| 2020-02-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-09 | 개시 | Piper Sandler | Overweight |
| 2019-03-01 | 개시 | RBC Capital Mkts | Outperform |
| 2018-11-16 | 개시 | B. Riley FBR | Buy |
| 2017-12-13 | 재확인 | H.C. Wainwright | Buy |
| 2017-10-23 | 재개 | ROTH Capital | Buy |
| 2017-09-07 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2017-06-08 | 개시 | Rodman & Renshaw | Neutral |
모두보기
Aptose Biosciences Inc 주식(APTO)의 최신 뉴스
Aptose gets Nasdaq extension to regain compliance - MSN
Aptose Announces Positive Decision by Nasdaq Hearings Panel - GlobeNewswire
Aptose Biosciences Secures Critical Nasdaq Extension, Unveils $8M Offering and Cancer Drug Progress - StockTitan
Metrics That Matter About Aptose Biosciences Inc (NASDAQ: APTO) - Stocks Register
SEC Form PRE 14A filed by Aptose Biosciences Inc. - Quantisnow
Aptose Announces Publication of Preclinical Data in AACR - GlobeNewswire
Aptose's Tuspetinib Shows Breakthrough Potential in Leukemia Treatment, Clinical Data Reveals Powerful Anti-Cancer Effects - StockTitan
Aptose Biosciences: Top 10 Undervalued Healthcare Sector Stocks On TSX (APS) - Barchart
Aptose Clinical Data Featured in Poster Presentation at the - GlobeNewswire
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML - Marketscreener.com
Aptose's Tuspetinib Shows Breakthrough 60% Response Rate in AML Treatment at ASH Meeting - StockTitan
StockNews.com Initiates Coverage on Aptose Biosciences (NASDAQ:APTO) - Defense World
Aptose Biosciences maintains shares target, Buy rating post-NCI deal By Investing.com - Investing.com Canada
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML - GlobeNewswire
Aptose Partners with NCI to Advance Tuspetinib Cancer Treatment in Clinical Trials - StockTitan
Aptose Biosciences Inc (APTO) Has A Gold Mine On Its Hands - Stocks Register
Aptose Biosciences CEO William Rice acquires $20,000 in shares By Investing.com - Investing.com Australia
Aptose Biosciences CEO William Rice acquires $20,000 in shares - Investing.com
Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering - GlobeNewswire
Aptose Biosciences Boosts Capital with $8M Offering - TipRanks
Aptose Biosciences Completes $8M Public Offering with Insider Participation | APTO Stock News - StockTitan
Form 424B4 Aptose Biosciences Inc. - StreetInsider.com
SEC Form 424B4 filed by Aptose Biosciences Inc. - Quantisnow
Aptose sets $8 million target in stock and warrant offering By Investing.com - Investing.com Australia
Stocks In Play: Aptose Biosciences Inc. By Baystreet.ca - Investing.com Canada
Crude Oil Gains Over 1%; Ross Stores Earnings Top Views - Benzinga
Aptose sets $8 million target in stock and warrant offering - Investing.com India
Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering - GlobeNewswire
Dow Jumps 300 Points; Gap Posts Upbeat Earnings - Benzinga
Aptose Biosciences Inc. - Baystreet.ca
Aptose Biosciences Announces $8 Million Public Offering - TipRanks
Aptose Biosciences Raises $8M in Public Offering with Warrant Package at $0.20 Per Share | APTO Stock News - StockTitan
Why Elastic Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket - Benzinga
Aptose Biosciences stock plunges to 52-week low of $0.33 By Investing.com - Investing.com Canada
Aptose Biosciences stock plunges to 52-week low of $0.33 - Investing.com India
Aptose Initiates TUSCANY Phase 1/2 Study for Newly - GlobeNewswire
Aptose Launches Phase 1/2 Trial Testing Novel AML Triplet Therapy with Tuspetinib | APTO Stock News - StockTitan
ARMISTICE CAPITAL, LLC Increases Stake in Aptose Biosciences Inc - GuruFocus.com
Aptose Biosciences Inc. (APTO) Quarterly 10-Q Report - Quartz
Aptose Biosciences Reports Q3 2024 Financial Highlights - TipRanks
Aptose Reports Results for the Third Quarter 2024 - GlobeNewswire
Aptose Biosciences Cuts Q3 Losses, Secures $10M Loan Amid Nasdaq Challenges | APTO Stock News - StockTitan
RNA-based Therapeutics Market Latest Trends Analysis Report 2024 - InsightAce Analytic
Hanmi and MEDiC ink cancer biomarker collaboration deal - Pharmaceutical Technology
Aptose Biosciences faces delisting from NASDAQ - Investing.com India
Aptose Biosciences faces delisting from NASDAQ By Investing.com - Investing.com South Africa
Analysts’ New Coverage for September 18th (AINC, AIRI, APTO, ARM, AVGO, BGNE, CAN, CARA, CHH, CLLS) - Defense World
Aptose Biosciences secures shareholder nod for warrant issuance - Investing.com
Aptose Biosciences stock hits 52-week low at $0.34 - Investing.com
Aptose Biosciences Inc (APTO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):